Your browser doesn't support javascript.
loading
Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.
Paul, Abhik; Nahar, Sourin; Nahata, Pankaj; Sarkar, Arnab; Maji, Avik; Samanta, Ajeya; Karmakar, Sanmoy; Maity, Tapan Kumar.
Afiliação
  • Paul A; Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700 032, India. Electronic address: abhik.jupharm@gmail.com.
  • Nahar S; Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700 032, India. Electronic address: sourinnahar1913@gmail.com.
  • Nahata P; Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700 032, India. Electronic address: pankajnahata1996@gmail.com.
  • Sarkar A; Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700 032, India; Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700032, India. Electronic address: sarkar.arnab54@yahoo.com.
  • Maji A; Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700 032, India. Electronic address: avikmaji.pharma.rs@jadavpuruniversity.in.
  • Samanta A; Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700 032, India. Electronic address: ajeyas.pharma.rs@jadavpuruniversity.in.
  • Karmakar S; Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700 032, India; Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700032, India. Electronic address: sanmoy.karmakar@jadavpuruniversity.in.
  • Maity TK; Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700 032, India. Electronic address: tapan.maity@jadavpuruniversity.in.
Eur J Med Chem ; 264: 115990, 2024 Jan 15.
Article em En | MEDLINE | ID: mdl-38039791
Free fatty acid receptor 1 (FFAR1 or GPR40) is a potential target for treating type 2 diabetes mellitus (T2DM) and related disorders that have been extensively researched for many years. GPR40/FFAR1 is a promising anti-diabetic target because it can activate insulin, promoting glucose metabolism. It controls T2DM by regulating glucose levels in the body through two separate mechanisms: glucose-stimulated insulin secretion and incretin production. In the last few years, various synthetic GPR40/FFAR1 agonists have been discovered that fall under several chemical classes, viz. phenylpropionic acid, phenoxyacetic acid, and dihydrobenzofuran acetic acid. However, only a few synthetic agonists have entered clinical trials due to various shortcomings like poor efficacy, low lipophilicity and toxicity issues. As a result, pharmaceutical firms and research institutions are interested in developing synthetic GPR40/FFAR1 agonists with superior effectiveness, lipophilicity, and safety profiles. This review encompasses the most recent research on synthetic GPR40/FFAR1 agonists, including their chemical classes, design strategies and structure-activity relationships. Additionally, we have emphasised the structural characteristics of the most potent GPR40/FFAR1 agonists from each chemical class of synthetic derivatives and analysed their chemico-biological interactions. This work will hopefully pave the way for developing more potent and selective synthetic GPR40/FFAR1 agonists for treating T2DM and related disorders.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article